EUROFINS SCIENTIFIC SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.84 EUR | -7.73% |
|
-3.53% | -3.63% |
| Apr. 24 | CAC40: interest rates soar, pulling back below 8100 pts | CF |
| Apr. 24 | EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed |  |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 27.92 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.63% | 12.71B | A- | ||
| -14.17% | 86.34B | B- | ||
| +17.86% | 84.49B | C+ | ||
| +10.92% | 29.68B | C+ | ||
| -8.51% | 17.5B | B | ||
| -2.67% | 16.67B | A- | ||
| -0.24% | 15.18B | A- | ||
| +2.63% | 12.53B | A- | ||
| -30.53% | 11.89B | - | - | |
| +26.71% | 11.74B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE
